By
From the * Laboratory of Molecular Immunoregulation, An intact chemotactic response is vital for leukocyte trafficking and host defense. Opiates are
known to exert a number of immunomodulating effects in vitro and in vivo, and we sought to determine whether they were capable of inhibiting chemokine-induced directional migration
of human leukocytes, and if so, to ascertain the mechanism involved. The endogenous opioid
met-enkephalin induced monocyte chemotaxis in a pertussis toxin-sensitive manner. Met-enkephalin, as well as morphine, inhibited IL-8-induced chemotaxis of human neutrophils and
macrophage inflammatory protein (MIP)-1 Long-term abuse of opiates results in immune defects,
including impaired NK cell activity and altered CD4+
and CD8+ T cell numbers (1), and it has been implicated as
a contributing factor in HIV infection (2). In animal models, parenteral use of opiates has been demonstrated to inhibit mitogenic and effector cell responses in B and T cells
(3, 4), cellular immunity (5), phagocytosis by neutrophils
and macrophages (6, 7), tumor cell suppression (6, 7), and
cytokine production (8). Morphine inhibits monocyte and
neutrophil functions through the physiologically defined
µ3 opiate receptor (9, 10); indeed, binding sites and protein
expression for Chemokines are a large family of chemotactic cytokines
that mediate their effects on leukocytes through a number
of G protein-coupled, seven transmembrane-spanning
(STM)1 receptors (16). Although there is apparent redundancy in the ligand binding characteristics of these chemokine
receptors, specificity is provided by patterns of receptor and
G protein expression, ligand potency, and levels of receptor
desensitization. Interactions among STM receptors are complex (17): in a process known as receptor cross-regulation,
or heterologous desensitization, thrombin receptor activation has been shown to cause phosphorylation of several
chemoattractant receptors, including the IL-8 receptor CXCR1, the C5a receptor, and the receptor for platelet-activating factor, but not that for FMLP (18). Such cross-regulation does not occur between all classes of STM receptors; for example, Cells.
Intramural
Research Support Program, Science Applications International Corp. Frederick, Frederick, Maryland
21702; the § ABL-Basic Research Program, National Cancer Institute - Frederick Cancer Research
and Development Center, Frederick, Maryland 21702; the
Laboratory of Immunology, National
Institute on Aging, Baltimore, Maryland 21224; and the ¶ Department of Medicine, Duke University
Medical Center, Durham, North Carolina 27710
Abstract
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
, regulated upon activation, normal T expressed
and secreted (RANTES), and monocyte chemoattractant protein 1, but not MIP-1
-induced
chemotaxis of human monocytes. This inhibition of chemotaxis was mediated by
and µ but
not
G protein-coupled opiate receptors. Calcium flux induced by chemokines was unaffected by met-enkephalin pretreatment. Unlike other opiate-induced changes in leukocyte
function, the inhibition of chemotaxis was not mediated by nitric oxide. Opiates induced
phosphorylation of the chemokine receptors CXCR1 and CXCR2, but neither induced internalization of chemokine receptors nor perturbed chemokine binding. Thus, inhibition of
chemokine-induced chemotaxis by opiates is due to heterologous desensitization through phosphorylation of chemokine receptors. This may contribute to the defects in host defense
seen with opiate abuse and has important implications for immunomodulation induced by several endogenous neuropeptides which act through G protein-coupled receptors.
Introduction
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
and
subclasses of G protein-coupled opiate receptors (11, 12), in addition to gene expression of
,
, and µ subclasses (13), have been described in leukocytes.
1-adrenergic receptors are unable to
desensitize chemoattractant receptors (19). We have shown
recently that homologous desensitization through phosphorylation of the IL-8 receptor CXCR2 occurs in response to its native ligands IL-8 and neutrophil-activating
peptide (NAP)-2 (20). Together, these findings led us to
the hypothesis that the impairment of leukocyte functions
mediated by opiates may involve inhibition of chemokine
effects based on cross-regulation, resulting in phosphorylation and hence to heterologous desensitization of chemokine receptors. The studies reported here show that opiates, acting through
and µ subclasses of opiate receptors expressed on human monocytes and neutrophils, are capable
of inhibiting subsequent migratory responses to chemokines,
and that this process of heterologous desensitization or transdeactivation is associated with phosphorylation of chemokine receptors.
Materials and Methods
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
Chemotaxis.
In vitro chemotaxis was performed as described previously (22). In brief, cells were incubated at 37°C with medium, pertussis toxin (Sigma Chemical Co., St. Louis, MO) 500 ng/ml for 90 min, met-enkephalin (Sigma Chemical Co.) in varying concentrations for 60 min, naloxone (Sigma Chemical Co.) 10Intracellular Calcium Flux.
Human peripheral blood monocytes and neutrophils were incubated at 107/ml for 30 min at room temperature in HBSS containing 0.1% BSA and 1 µM Fura-2 (23). Cells were then washed in PBS and incubated with met-enkephalin (10Assessment of Receptor Internalization Using Confocal Laser Microscopy.
Rat basophil leukemia cells (RBL2H3) stably transfected to express CXCR1 were derived as described previously (24). Transfected cells were untreated or incubated with IL-8 1 µg/ml for 30 min or with met-enkephalin 10Binding Assays.
Binding of chemokines to their receptors was assessed using 1 ng/ml of 125I-labeled chemokine (NEN Research Products, Boston, MA) in the presence of various concentrations of unlabeled ligands or met-enkephalin (from equimolar to 1,000-fold excess), or after preincubation of the cells with met-enkephalin for 60 min with or without pretreatment for 10 min with naloxone. Cells at 107/ml in RPMI 1640/1% BSA/25 mM Hepes were incubated with ligands for 45 min at room temperature and pelleted through 10% sucrose; cell pellet-associated radioactivity was then determined in aChemokine Receptor Phosphorylation.
Epitope-tagged FMLP receptor-transfected (25) and CXCR1-transfected RBL2H3 cells were washed, then incubated in phosphate-free media for 3 h. The cells were then labeled with 150 µCi/7.5 × 106 cells of [32P]orthophosphate (NEN Research Products) for 90 min at 37°C before stimulation with native ligands for 5 min, met-enkephalin 10 ![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We
sought initially to confirm previous reports (26, 27) that
opiate compounds, including met-enkephalin, are chemotactic for monocytes and neutrophils. Preliminary studies
confirmed that phagocytes respond chemotactically, with a
chemotaxis index 2-2.5-fold higher than controls, to met-enkephalin and morphine, with optimal activity at 109
and 10
6 M, respectively. This chemotaxis was inhibited by
the opiate receptor antagonist naloxone (data not shown).
To investigate the mechanism of chemotaxis, monocytes
were incubated for 90 min with pertussis toxin 500 ng/ml
before exposure to met-enkephalin in microchemotaxis
chambers. Fig. 1 demonstrates that the chemotactic activity
of met-enkephalin for monocytes was abolished completely by pertussis toxin, suggesting association with the Gi
subclass of G proteins.
|
The immunosuppressive and antiinflammatory effects of
opiates led us to assess the ability of met-enkephalin to
downregulate chemotaxis of monocytes in response to
macrophage-inflammatory protein (MIP)-1 and monocyte chemoattractant protein (MCP)-1. Preincubation of
freshly isolated human monocytes for 60 min with met-enkephalin at concentrations of 10
15-10
6 M demonstrated that the optimal concentration for inhibition of
MIP-1
and MCP-1-induced chemotaxis was equivalent
to the optimal chemotactic dose, 10
9 M (Fig. 2). This
concentration, as well as the peak chemotactic concentration of 10
6 M for morphine, was used in subsequent inhibition experiments.
|
We next assessed the effect of preincubation of monocytes with met-enkephalin on chemotaxis in response to a
number of CC chemokines. MIP-1, regulated upon activation, normal T expressed and secreted (RANTES), and
MCP-1 at their optimal concentrations of 50 ng/ml were
potent inducers of monocyte chemotaxis but were inhibited by 82, 58, and 52%, respectively, by met-enkephalin (Fig. 3 A). These inhibitory effects were prevented by preincubation with 10
8 M naloxone. In contrast, chemotaxis
in response to MIP-1
was not inhibited by met-enkephalin (Fig. 3 A). Although MIP-1
and RANTES act through a
number of CC chemokine receptors, including CCR1,
CCR3, and CCR5, MIP-1
acts principally through CCR5
(28). These data suggest that some but not all CC chemokine receptors can be inhibited by met-enkephalin, and
that the degree of inhibition varies between receptors. Preincubation of monocytes with met-enkephalin also had no
effect on chemotaxis induced by FMLP (Fig. 3 A), indicating that the monocyte FMLP receptor, like its neutrophil
counterpart, is spared.
|
Preincubation of human neutrophils with met-enkephalin 109 M resulted in 61% inhibition of chemotaxis induced by 100 ng/ml IL-8 (Fig. 3 B). Inhibition was reversed by the presence of 10
8 M naloxone during the
incubation period, suggesting that this enkephalin-induced
effect was opiate receptor-mediated. Naloxone alone, although thought to act as a partial agonist for opiate receptors (29), was ineffective at inhibiting chemotaxis in response
to IL-8 (Fig. 3 B). Importantly, FMLP-induced chemotaxis of neutrophils was not inhibited by preincubation with
met-enkephalin (Fig. 3 B), indicating that the opiate effect
does not apply to all chemoattractant STM receptors.
To determine the potential
role of morphine in inhibiting chemokine effects and to
dissect opiate receptor specificity, monocytes were preincubated with morphine and certain opiate receptor-specific agonists, then tested for their chemotactic response to MIP-1. Like met-enkephalin, morphine caused significant inhibition (86%) of MIP-1
-induced chemotaxis of monocytes
(Fig. 4 A), which was reversed by naloxone. Since morphine is thought to mediate its effects in monocytes primarily through µ3 receptors (30), we examined the response of
monocytes to the µ opiate receptor-selective peptide
DAMGO ([D-ala2,N-me-phe-gly5(ol)]-enkephalin). Pretreatment with this compound at 10
9 M also resulted in
significant inhibition of MIP-1
chemotaxis (76%; Fig. 4
A). Moreover, the
-selective agonist dermenkephalin at 5 × 10
8 M inhibited MIP-1
chemotaxis by 52%, whereas the
-selective agonist dynorphin A at 10
8 M caused no significant inhibition (Fig. 4 A). Similar results were observed for
neutrophils: DAMGO and dermenkephalin inhibited IL-8-induced chemotaxis by 50 and 34%, respectively, whereas
dynorphin A had no effect (data not shown). Together,
these results suggest that opiate-mediated inhibition of
chemokine-induced chemotaxis occurs through activation
of µ and
but not
opiate receptors expressed on monocytes and neutrophils.
|
To clarify opiate receptor specificity further, monocytes
and neutrophils were incubated with the µ-specific antagonist CTOP (cys2, tyr3, orn5, pen7 amide) at 107 M or the
-selective antagonist naltrindole at 2 × 10
8 M before
met-enkephalin. CTOP reversed 67% of the met-enkephalin-induced inhibition of MIP-1
-induced monocyte chemotaxis, whereas naltrindole reversed 30% (Fig. 4 B), indicating a greater effect through µ than through
opiate receptors
on monocytes. Combining these antagonists before met-enkephalin treatment reversed completely the met-enkephalin
effect. Similarly, preincubation of neutrophils with the µ receptor antagonist CTOP and with the
antagonist naltrindole reversed 66 and 46% of the met-enkephalin-mediated inhibition of IL-8-induced chemotaxis, respectively
(data not shown).
In addition to their ability to
generate chemotaxis of leukocytes, chemokines induce intracellular Ca2+ fluxes in many responding cells. Met-enkephalin and morphine were assessed for their ability to
induce changes in intracellular Ca2+ concentration, and for
any activity in heterologously reducing chemokine-induced
Ca2+ mobilization. There was no evidence of direct induction of Ca2+ flux by met-enkephalin in monocytes, nor did
preincubation with varying concentrations of met-enkephalin
alter the Ca2+ flux induced by activating doses of MIP-1
(Fig. 5). Analysis of the effect of met-enkephalin on the
EC50 of MIP-1
demonstrated a Ca2+ flux response at low
doses. Peak Ca2+ flux occurred using 10 ng/ml MIP-1
,
and the EC50 was ~2 ng/ml, with no significant difference
between untreated and met-enkephalin-pretreated monocytes
(data not shown). The chemokines IL-8, NAP-2, MCP-1, MCP-3, and RANTES, and the chemoattractant FMLP,
were also assessed in neutrophils and monocytes, as appropriate, and their capacity to induce Ca2+ flux was similarly
unaffected by met-enkephalin or morphine pretreatment (data not shown).
|
To determine if the ability of
opiates to inhibit chemokine-induced chemotaxis arises
through chemokine receptor internalization, epitope-tagged CXCR1-transfected RBL2H3 cells (24) were examined by confocal laser microscopy. Initial experiments
demonstrated that these cells responded chemotactically to
IL-8, and that this chemotactic effect was inhibited in a
naloxone-sensitive manner by met-enkephalin pretreatment, confirming the presence of functional opiate receptors (data not shown). After preincubation with IL-8 1 µg/
ml for 30 min, the transfected cells showed prominent internalization of CXCR1, but no internalization was seen in
response to preincubation for 60 min using met-enkephalin
109 M (Fig. 6). Similar observations were made for CXCR2
on human neutrophils and CCR5 on human monocytes
(data not shown).
|
To confirm
the lack of receptor internalization in response to opiates,
we examined the ability of met-enkephalin to inhibit binding of CXC and CC chemokines to their specific receptors. Using 125I-labeled chemokines and met-enkephalin on
fresh human neutrophils and monocytes, there was no evidence in direct competition assays of binding of met-enkephalin to receptors for IL-8, NAP-2, MCP-1, MCP-2, MCP-3,
MIP-1, MIP-1
, or RANTES. Similarly, after preincubation of cells with met-enkephalin for 60 min, there was
no impairment of chemokine binding (Fig. 7), suggesting
that chemokine receptor affinity and number were not
modulated by this duration of met-enkephalin treatment.
Therefore, the observed met-enkephalin effects on chemotactic responses were not occurring at the level of chemokine receptor binding of ligands.
|
Recent data suggest that morphine-mediated effects in monocytes and neutrophils may be due
to the generation of NO (30). Monocytes treated with the
NO synthase inhibitor L-NMMA (NG-monomethyl-L-arginine monoacetate) before incubation with opiates showed
no change in the opiate-induced inhibition of MIP-1
chemotaxis, nor did the NO donor diethylamine dinitric
oxide (31) at 500 µM, which generates NO at a concentration ~104-fold higher than the inhibitory concentration
thought to be produced by morphine-stimulated monocytes (30), reproduce the opiate effect (data not shown).
Thus, opiate-induced inhibition of chemokine effects is
not mediated by NO.
Since opiate
molecules, like chemokines, mediate their actions through
STM receptors, the possibility that inhibition of chemokines occurred by a process of heterologous desensitization
was next examined. For technical reasons, analysis of
chemokine receptor phosphorylation in neutrophils and
monocytes was unsuccessful; in view of this, phosphorylation was examined in a receptor transfected cell system.
Epitope-tagged FMLP receptor-expressing and epitope-tagged CXCR1-expressing RBL2H3 cells were incubated
in phosphate-free medium, then with [32P]orthophosphate.
They were then stimulated with FMLP 106 M (for the
FMLP receptor-expressing cells), IL-8 500 ng/ml (for the
CXCR1-expressing cells), or met-enkephalin 10
9 M. After whole cell lysis, chemoattractant receptors were immunoprecipitated and examined on SDS-polyacrylamide gels
exposed to radiographic film (18). The results demonstrate
that in addition to the expected phosphorylation of the
chemoattractant receptors induced by the native ligands,
CXCR1 was phosphorylated in response to met-enkephalin (Fig. 8). This phosphorylation was inhibited by naloxone (Fig. 8). CXCR2 immunoprecipitated from retinoic
acid-differentiated U937 cells also was found to be phosphorylated after exposure of the cells to met-enkephalin
(data not shown). The FMLP receptor was not phosphorylated in response to met-enkephalin treatment (Fig. 8).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This paper describes for the first time a plausible and intriguing mechanism by which opiates may mediate the impaired leukocyte function observed in drug abusers and in
animal models of opiate abuse. It also suggests the possibility of an immunomodulatory role for endogenous opiates
in controlling leukocyte recruitment. It confirms earlier
studies (26, 27) showing that opiate molecules can act directly, albeit weakly, as chemoattractants, and demonstrates that this functional effect is pertussis toxin-sensitive, suggesting coupling of opiate receptors in monocytes to the
Gi subclass of G proteins. Although this has been shown
for opiate responses in hippocampal slices (32) and µ receptor-transfected Jurkat cells (33), to our knowledge this is
the first analysis of G protein use by opiate receptors on native leukocytes.
The heterologous desensitization of chemokine responses observed in these experiments has definite selectivity, since the FMLP receptor is unaffected and CCR5 may also be relatively spared, indicating that there is no generalized impairment of cell motility. The intracellular controls that generate this apparent selectivity remain to be clearly defined, although sparing of the FMLP receptor in heterologous phosphorylation processes has been observed previously and may reflect the absence of protein kinase C phosphorylation sites in intracellular portions of the receptor (18). A further clue to molecular mechanisms of opiate-induced desensitization is suggested by the lack of inhibition of chemokine-induced Ca2+ flux and absence of chemokine receptor internalization by opiates, despite both impairment of the chemotactic response and enhancement of receptor phosphorylation. These features imply a lower requirement for G protein activation by chemokine receptors for Ca2+ mobilization than for chemotaxis. Alternatively, by analogy with studies examining cross-regulation among chemoattractant receptors (34), there may be levels in addition to receptor phosphorylation at which desensitization occurs. Studies are planned to identify the roles of various receptor kinases and intracellular receptor residues involved in the divergent desensitization responses observed here.
The effects of met-enkephalin observed in monocytes
and neutrophils are mediated through µ and but not
opiate receptors. All three receptor types are known to be
expressed by leukocytes (11), and their differential ability to interact with chemokine receptors suggests the possibility of using specific receptor agonists as potential antiinflammatory molecules. The lack of efficacy of
agonists in
inhibiting chemokine effects contrasts with the ability of
receptor activation to inhibit replication of HIV-1 in microglial cells, the central nervous system equivalent of resident macrophages (15), suggesting divergence between blood monocytes and tissue macrophages in opiate receptor
expression or responsiveness. The molecular mechanisms
of opiate receptor selectivity in chemokine receptor desensitization remain to be elucidated. Although some opiate-mediated, and specifically morphine-mediated, effects on
leukocytes appear to involve NO-dependent devices (30), it is clear from our results that desensitization of chemokine responses by µ and
opiate receptor activation occurs independently of NO generation.
This study has broad implications for the inhibition of leukocyte responses by opiate molecules, and indeed by other apparently nonimmune mediators acting through STM receptors. The data suggest a mechanism by which opiates function as antiinflammatory or immunosuppressive agents, by interfering with chemokine-induced directional migration of inflammatory cells. That inhibition or absence of chemokines can markedly suppress inflammatory reactions has been demonstrated in several animal models of disease by administration of neutralizing antibodies (35, 36), as well as in virally infected chemokine deletion mutants (37). Therefore, exposure of leukocytes to opiates in vivo may result in profoundly impaired host responses. This may have direct clinical relevance, such as in the setting of analgesia given in the presence of infectious or surgical insults or in the intravenous drug user exposed to infectious agents. However, this study may also have relevance in the potential modulation of immune and inflammatory responses due to endogenous opiate molecules, which among other neuropeptides are known to be released by cells of the immune system (38), and which may act as normal regulators of chemotaxis. These molecules also may play a role in altering inflammatory responses in pathophysiological states such as septic shock (39). Moreover, the finding of opiate-induced neuroimmunomodulation of chemokine function raises the prospect that other neuroendocrine mediators, acting through STM receptors, might operate through similar mechanisms, a possibility we are currently investigating.
![]() |
Footnotes |
---|
Address correspondence to Michael C. Grimm, Laboratory of Molecular Immunoregulation, National Cancer Institute - Frederick Cancer Research and Development Center, Bldg. 560, Rm. 31-19, Frederick, MD 21702-1201. Phone: 301-846-1347; Fax: 301-846-7042; E-mail: grimm{at}mail.ncifcrf.gov
Received for publication 10 July 1997 and in revised form 24 April 1998.
This research is sponsored in part by the National Cancer Institute, Department of Health and Human Services, under contract with ABL. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.The authors are grateful to Dr. S.-B. Su for assisting with calcium mobilization experiments; to Drs. P.M. Murphy (National Institute of Allergy and Infectious Diseases, Bethesda, MD), A. Richmond (Vanderbilt University, Nashville, TN), and C. Hébert (Genentech Inc., San Francisco, CA) for supplying antibodies; to Dr. G. Cox of Science Applications International Corp., Frederick, and Dr. R. Shen of ABL-Basic Research Program, National Cancer Institute - Frederick Cancer Research and Development Center, for their helpful advice; and to Drs. R. Neta and S. Durum for reviewing the manuscript.
Abbreviations used in this paper CCR, CC chemokine receptor; CXCR, CXC chemokine receptor; CTOP, cys2, tyr3, orn5, pen7 amide; DAMGO, [D-ala2,N-me-phe-gly5(ol)]-enkephalin; MCP, monocyte chemoattractant protein; MIP, macrophage-inflammatory protein; NAP, neutrophil-activating peptide; NO, nitric oxide; RANTES, regulated upon activation, normal T expressed and secreted; STM, seven transmembrane-spanning.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Novick, D.M., M. Ochshorn, V. Ghali, T.S. Croxson, W.D. Mercer, N. Chiorazzi, and M.J. Kreek. 1989. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 250: 606-610 [Abstract]. |
2. | Donahoe, R.M., and A. Falek. 1988. Neuroimmunomodulation by opiates and other drugs of abuse: relationship to HIV infection and AIDS. In Psychological, Neuropsychiatric, and Substance Abuse Aspects of AIDS. T.P. Bridge, A.F. Mirsky, and F.K. Goodwin, editors. Raven Press, Ltd., New York. 145-158. |
3. | Bryant, H.U., E.W. Bernton, and J.W. Holaday. 1987. Immunosuppressive effects of chronic morphine treatment in mice. Life Sci. 41: 1731-1738 [Medline]. |
4. |
Taub, D.D.,
T.K. Eisenstein,
E.B. Geller,
M.W. Adler, and
T.J. Rogers.
1991.
Immunomodulatory activity of µ- and
![]() |
5. | Pellis, N.R., C. Harper, and N. Dafny. 1986. Suppression of the induction of delayed hypersensitivity in rats by repetitive morphine treatments. Exp. Neurol. 93: 92-97 [Medline]. |
6. | Tubaro, E., G. Borelli, C. Croce, G. Cavallo, and C. Santiangeli. 1983. Effect of morphine on resistance to infection. J. Infect. Dis. 148: 656-666 [Medline]. |
7. | Pacifici, R., G. Patrini, I. Venier, D. Parolaro, P. Zuccaro, and E. Gori. 1994. Effect of morphine and methadone acute treatment on immunological activity in mice: pharmacokinetic and pharmacodynamic correlates. J. Pharmacol. Exp. Ther. 269: 1112-1116 [Abstract]. |
8. | Bhargava, H.N., P.T. Thomas, S. Thorat, and R.V. House. 1994. Effects of morphine tolerance and abstinence on cellular immune function. Brain Res. 642: 1-10 [Medline]. |
9. | Stefano, G.B., A. Digenis, S. Spector, M.K. Leung, T.V. Bilfinger, M.H. Makman, B. Scharrer, and N.N. Abumrad. 1993. Opiate-like substances in an invertebrate, an opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression. Proc. Natl. Acad. Sci. USA. 90: 11099-11103 [Abstract]. |
10. |
Makman, M.H.,
T.V. Bilfinger, and
G.B. Stefano.
1995.
Human granulocytes contain an opiate alkaloid-selective receptor mediating inhibition of cytokine-induced activation and
chemotaxis.
J. Immunol.
154:
1323-1330
|
11. |
Carr, D.J.,
C.H. Kim,
B. deCosta,
A.E. Jacobson,
K.C. Rice, and
J.E. Blalock.
1988.
Evidence for a ![]() |
12. |
Carr, D.J.,
B.R. deCosta,
C.H. Kim,
A.E. Jacobson,
V. Guarcello,
K.C. Rice, and
J.E. Blalock.
1989.
Opioid receptors on
cells of the immune system: evidence for ![]() ![]() |
13. | Chuang, L.F., T.K. Chuang, K.F. Killam Jr., A.J. Chuang, H.F. Kung, L. Yu, and R.Y. Chuang. 1994. Delta opioid receptor gene expression in lymphocytes. Biochem. Biophys. Res. Commun. 202: 1291-1299 [Medline]. |
14. | Chuang, T.K., K.F. Killam Jr., L.F. Chuang, H.F. Kung, W.S. Sheng, C.C. Chao, L. Yu, and R.Y. Chuang. 1995. Mu opioid receptor gene expression in immune cells. Biochem. Biophys. Res. Commun. 216: 922-930 [Medline]. |
15. |
Chao, C.C.,
G. Gekker,
S. Hu,
W.S. Sheng,
K.B. Shark,
D.-F. Bu,
S. Archer,
J.M. Bidlack, and
P.K. Peterson.
1996.
![]() |
16. | Murphy, P.M.. 1996. Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev. 7: 47-64 . [Medline] |
17. | Snyderman, R., and R.J. Uhing. 1992. Chemoattractant stimulus-response coupling. In Inflammation: Basic Principles and Clinical Correlates. 2nd ed. J.I. Gallin, I.M. Goldstein, and R. Snyderman, editors. Raven Press, Ltd., New York. 421-439. |
18. |
Ali, H.,
E.D. Tomhave,
R.M. Richardson,
B. Haribabu, and
R. Snyderman.
1996.
Thrombin primes responsiveness of selective chemoattractant receptors at a site distal to G protein
activation.
J. Biol. Chem.
271:
3200-3206
|
19. | Didsbury, J.R., R.J. Uhing, E. Tomhave, C. Gerard, N. Gerard, and R. Snyderman. 1991. Receptor class desensitization of leukocyte chemoattractant receptors. Proc. Natl. Acad. Sci. USA. 88: 11564-11568 [Abstract]. |
20. | Ben-Baruch, A., M. Grimm, K. Bengali, G.A. Evans, O. Chertov, J.M. Wang, O.M.Z. Howard, N. Mukaida, K. Matsushima, and J.J. Oppenheim. 1997. The differential ability of IL-8 and NAP-2 to induce attenuation of chemotaxis is mediated by their divergent capabilities to phosphorylate CXCR2 (IL-8RB). J. Immunol. 158: 5927-5933 [Abstract]. |
21. | Johnston, J.A., D.K. Ferris, J.M. Wang, D.L. Longo, J.J. Oppenheim, and D.J. Kelvin. 1994. Staurosporine restores signaling and inhibits interleukin-8-induced chemotactic desensitization. Eur. J. Immunol. 24: 2556-2562 [Medline]. |
22. | Wang, J.M., D.W. McVicar, J.J. Oppenheim, and D.J. Kelvin. 1993. Identification of RANTES receptors on human monocytic cells: competition for binding and desensitization by homologous chemotactic cytokines. J. Exp. Med. 177: 699-705 [Abstract]. |
23. | Badolato, R., J.A. Johnston, J.M. Wang, D. McVicar, L.L. Xu, J.J. Oppenheim, and D.J. Kelvin. 1995. Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J. Immunol. 155: 4004-4010 [Abstract]. |
24. | Richardson, R.M., R.A. DuBose, H. Ali, E.D. Tomhave, B. Haribabu, and R. Snyderman. 1995. Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions. Biochemistry. 34: 14193-14201 [Medline]. |
25. |
Ali, H.,
R.M. Richardson,
E.D. Tomhave,
J.R. Didsbury, and
R. Snyderman.
1993.
Differences in phosphorylation of
formylpeptide and C5a chemoattractant receptors correlate
with differences in desensitization.
J. Biol. Chem.
268:
24247-24254
|
26. | Simpkins, C.O., C.A. Dickey, and M.P. Fink. 1984. Human neutrophil migration is enhanced by beta-endorphin. Life Sci. 34: 2251-2255 [Medline]. |
27. |
Van Epps, D.E., and
L. Saland.
1984.
![]() |
28. | Samson, M., O. Labbe, C. Mollereau, G. Vassart, and M. Parmentier. 1996. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 35: 3362-3367 [Medline]. |
29. | Goldstein, A.. 1973. Interactions of narcotic antagonists with receptor sites. Adv. Biochem. Psychopharmacol. 8: 471-481 [Medline]. |
30. |
Magazine, H.I.,
Y. Liu,
T.V. Bilfinger,
G.L. Fricchione, and
G.B. Stefano.
1996.
Morphine-induced conformational changes
in human monocytes, granulocytes, and endothelial cells and
in invertebrate immunocytes and microglia are mediated by
nitric oxide.
J. Immunol.
156:
4845-4850
|
31. | Sheffler, L.A., D.A. Wink, G. Melillo, and G.W. Cox. 1995. Characterization of nitric oxide-stimulated ADP-ribosylation of various proteins from the mouse macrophage cell line ANA-1 using sodium nitroprusside and the novel nitric oxide-donating compound diethylamine dinitric oxide. J. Leukocyte Biol. 57: 152-159 [Abstract]. |
32. |
Dunwiddie, T.V., and
M.T. Su.
1988.
Pertussis toxin pretreatment antagonizes the actions of µ- and ![]() |
33. |
Sharp, B.M.,
N.A. Shahabi,
W. Heagy,
K. McAllen,
M. Bell,
C. Huntoon, and
D.J. McKean.
1996.
Dual signal transduction through ![]() |
34. |
Richardson, R.M.,
H. Ali,
E.D. Tomhave,
B. Haribabu, and
R. Snyderman.
1995.
Cross-desensitization of chemoattractant receptors occurs at multiple levels![]() |
35. |
Broaddus, V.C.,
A.M. Boylan,
J.M. Hoeffel,
K.J. Kim,
M. Sadick,
A. Chuntharapai, and
C.A. Hébert.
1994.
Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of
endotoxin-induced pleurisy.
J. Immunol.
152:
2960-2967
|
36. | Wada, T., N. Tomosugi, T. Naito, H. Yokoyama, K. Kobayashi, A. Harada, N. Mukaida, and K. Matsushima. 1994. Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental immune complex-induced glomerulonephritis. J. Exp. Med. 180: 1135-1140 [Abstract]. |
37. |
Cook, D.N.,
M.A. Beck,
T.M. Coffman,
S.L. Kirby,
J.F. Sheridan,
I.B. Pragnell, and
O. Smithies.
1995.
Requirement
of MIP-1![]() |
38. | Blalock, J.E.. 1994. The syntax of immune-neuroendocrine communication. Immunol. Today. 15: 504-511 [Medline]. |
39. | Harbour, D.V., F.S. Galin, T.K. Hughes, E.M. Smith, and J.E. Blalock. 1991. Role of leukocyte-derived pro-opiomelanocortin peptides in endotoxic shock. Circ. Shock. 35: 181-191 [Medline]. |